Fenofibrate 160 mg, a commonly prescribed cholesterol-lowering medication used to treat dyslipidemia, hypertriglyceridemia, and mixed lipid disorders, is included in the prescription drug FENOFIBRON 160. Fenofibrate is a member of the fibrate drug class, which mainly works by activating PPAR-α, or peroxisome proliferator-activated receptor alpha. Increased triglyceride-rich lipoprotein breakdown, improved very low-density lipoprotein (VLDL) clearance, and slight increases in high-density lipoprotein (HDL) cholesterol are the results of this activation.

FENOFIBRON 160 helps lower the risk of cardiovascular events, such as heart attacks and strokes, and is especially helpful for people with high triglycerides, low HDL cholesterol, or mixed dyslipidemia. The 160 mg formulation offers straightforward dosage and efficient lipid control, and it is suited for once-daily consumption.

Uses

FENOFIBRON 160 is indicated for several lipid-related conditions:

1. Hypertriglyceridemia

Fenofibrate effectively lowers triglyceride levels, reducing the risk of pancreatitis associated with severely elevated triglycerides.

2. Mixed Dyslipidemia

FENOFIBRON 160 helps reduce total cholesterol, low-density lipoprotein (LDL), and VLDL, while increasing protective HDL cholesterol, improving the overall lipid profile.

3. Cardiovascular Risk Reduction

By correcting lipid imbalances, Fenofibrate contributes to reducing atherosclerotic plaque formation, lowering the risk of coronary artery disease, stroke, and other cardiovascular events.

4. Adjunct Therapy

FENOFIBRON 160 can be combined with statins or lifestyle interventions for patients requiring additional lipid-lowering therapy when monotherapy is insufficient.

5. Metabolic Syndrome Management

Patients with metabolic syndrome and elevated triglycerides benefit from Fenofibrate therapy, which addresses multiple lipid abnormalities simultaneously.

Through these indications, FENOFIBRON 160 offers comprehensive lipid control, reducing cardiovascular risks and promoting metabolic health.

Benefits

FENOFIBRON 160 provides multiple clinical and patient-centered benefits:

1. Effective Triglyceride Reduction

By enhancing lipoprotein breakdown, Fenofibrate significantly reduces serum triglyceride levels, protecting against acute pancreatitis.

2. Improved Cholesterol Profile

It increases HDL cholesterol and lowers LDL cholesterol, supporting cardiovascular health and reducing atherosclerotic risk.

3. Cardiovascular Protection

Long-term therapy with FENOFIBRON 160 reduces the incidence of cardiovascular events, particularly in high-risk patients with dyslipidemia and metabolic syndrome.

4. Convenient Once-Daily Dosing

The 160 mg tablet supports once-daily intake, improving adherence in chronic therapy.

5. Well-Tolerated Therapy

FENOFIBRON 160 is generally well-tolerated, with a favorable safety profile when monitored appropriately, making it suitable for long-term lipid management.

6. Supports Comprehensive Management

When combined with dietary modifications, exercise, and other lipid-lowering agents, FENOFIBRON 160 ensures optimal cardiovascular and metabolic health outcomes.

These benefits make FENOFIBRON 160 a trusted and effective therapy for patients with lipid disorders and increased cardiovascular risk.

Dosage

The dosage of FENOFIBRON 160 should be individualized according to the patient’s lipid profile, cardiovascular risk, and renal function.

Recommended Dosage:

• Typical Dose: One tablet of FENOFIBRON 160 mg once daily.

• Administration: Swallow the tablet with water, preferably after a meal to enhance absorption.

• With Food: Taking the tablet with food improves bioavailability and reduces gastrointestinal discomfort.

Dose Adjustment:

• In patients with moderate renal impairment, dose adjustment or careful monitoring may be necessary.

• For patients on combination therapy with statins, regular liver function tests and kidney function monitoring are recommended.

• Therapy should be accompanied by lifestyle interventions such as dietary modification, weight management, and exercise for optimal results.

Proper adherence ensures maximum efficacy while minimizing adverse effects.

Side Effects

FENOFIBRON 160 is generally well-tolerated, but patients may experience side effects related to fibrate therapy.

Common Side Effects:

• Mild gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea

• Headache or dizziness

• Muscle pain or fatigue

Less Common but Serious Side Effects:

• Myopathy or rhabdomyolysis, especially when combined with statins

• Liver enzyme elevations or hepatotoxicity

• Kidney function impairment in susceptible individuals

• Allergic reactions including rash or swelling

Patients should report persistent muscle pain, weakness, jaundice, or dark urine immediately to prevent serious complications.

Precautions and Warning

Before prescribing FENOFIBRON 160, healthcare providers should consider several precautions:

1. Kidney Function Monitoring

Regular checks of serum creatinine and kidney function are recommended, particularly in elderly patients or those with pre-existing renal impairment.

2. Liver Function Monitoring

Baseline and periodic liver enzyme tests are advised, as Fenofibrate may affect hepatic function in some patients.

3. Muscle Health Monitoring

Patients should report muscle pain or weakness, especially when taking concurrent statins, to prevent myopathy or rhabdomyolysis.

4. Pregnancy and Lactation

Use only if clearly indicated, as the safety of Fenofibrate during pregnancy and lactation is not well established.

5. Drug Interactions

Inform your healthcare provider about other medications, particularly statins, anticoagulants, and antihypertensives, to avoid potential interactions.

6. Lifestyle Considerations

Adherence to dietary modifications, exercise, and regular monitoring is essential to maximize therapeutic benefits.

Conclusion

FENOFIBRON 160, containing Fenofibrate 160 mg, is a clinically proven and safe lipid-lowering agent that provides effective management of hypertriglyceridemia, mixed dyslipidemia, and cardiovascular risk reduction. By modulating lipid metabolism through PPAR-α activation, it lowers triglycerides, increases HDL cholesterol, and improves overall lipid profile, supporting cardiovascular health.

With once-daily dosing, evidence-based efficacy, and favorable tolerability, FENOFIBRON 160 is a reliable choice for healthcare providers in India seeking to deliver long-term lipid control and cardiovascular protection. When combined with lifestyle modifications, dietary measures, and regular monitoring, it ensures improved patient outcomes, symptom management, and reduced cardiovascular events.